期刊文献+

罗格列酮对糖尿病大鼠肾脏IL-6、IL-8、TNF-α表达的影响 被引量:4

Effects of Rosiglitazone on IL-6,IL-8 and TNF-α Expression in the Kidney of Diabetic Rats
下载PDF
导出
摘要 目的观察罗格列酮对糖尿病大鼠肾脏炎症相关因子IL-6、IL-8和TNF-α表达的影响。方法雄性SD大鼠被分为正常组、正常+罗格列酮组、糖尿病组、糖尿病+罗格列酮组。所有大鼠均检测生化指标、尿白蛋白排泄率,及肾组织IL-6、IL-8、TNF-αmRNA和蛋白水平。结果罗格列酮干预的糖尿病大鼠和未干预组相比,肾组织IL-6、IL-8、TNF-α表达显著降低,尿白蛋白排泄减少,但血糖、肌酐无明显变化。结论罗格列酮可能通过抑制炎症相关因子的表达,从而降低尿白蛋白的排泄以保护肾脏,并且其作用独立于降糖之外。 Objective To observe the effects of Rosiglitazone on inflammatory cytokines expression in the kidney of diabetic rats.Methods Forty male SD rats were randomly divided into four groups:normal control group,normal control+Rosiglitazone group,diabetes group,diabetes+Rosiglitazone group.Diabetic nephropathy in rats was induced by intraperitoneal injection of streptozotocin(STZ,70 mg/kg)and the rats were killed after treatment for 8 weeks.Biochemical markers and urinary albumin excretion were measured.The expression levels of IL-6,IL-8 and TNF-α mRNA and protein were detected by real-time PCR and Western blot,respectively.Results As compared with untreated diabetic rats,Rosiglitazone significantly reduced the IL-6,IL-8 and TNF-α expression levels,and urinary albumin excretion in the kidney of diabetic rats.Meanwhile,there was no significant change in blood glucose and creatinine.Conclusion Rosiglitazone might improve renal function partly through inhibiting the inflammatory cytokine expression and reducing urinary albumin excretion in diabetic nephropathy.Furthermore,the protective effects of Rosiglitazone on the kidney were independent from its hypoglycemic effects.
出处 《华中科技大学学报(医学版)》 CAS CSCD 北大核心 2010年第6期802-805,共4页 Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
基金 国家自然科学基金资助项目(No.30800523)
关键词 糖尿病肾病 炎症因子 罗格列酮 diabetic nephropathy inflammatory cytokine Rosiglitazone
  • 相关文献

参考文献9

  • 1Remuzzi G,Ruggenenti P,Benigni A.Understanding the nature of renal disease progression[J].Kidney Int,1997,51(1):2-15.
  • 2Agewall S,Wikstrand J,Ljungman S,et al.Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus.Risk Factor Intervention Study Group[J].Am J Cardiol,1997,80(2):164-169.
  • 3Ceriello A.Thiazolidinediones as anti-inflammatory and anti-atherogenic agents[J].Diabetes Metab Res Rev,2008,24(1):14-26.
  • 4Ruster C,Wolf G.The role of chemokines and chemokine receptors in diabetic nephropathy[J].Front Biosci,2008,13(1):944-955.
  • 5Williams M D,Nadler J L.Inflammatory mechanisms of diabetic complications[J].Curr Diab Rep,2007,7(3):242-248.
  • 6Apostolakis S,Vogiatzi K,Amanatidou V,et al.Interleukin 8 and cardiovascular disease[J].Cardiovasc Res,2009,84(3):353-360.
  • 7Navarro J F,Milena F J,Mora C,et al.Renal pro-inflammatory cytokine gene expression in diabetic nephropathy:effect of angiotensin-converting enzyme inhibition and pentoxifylline administration[J].Am J Nephrol,2006,26(6):562-570.
  • 8Bakris G,Viberti G,Weston W M,et al.Rosiglitazone reduces urinary albumin excretion in type Ⅱ diabetes[J].J Hum Hypertens,2003,17(1):7-12.
  • 9Pistrosch F,Herbrig K,Kindel B,et al.Rosiglitazone impr-oves glomerular hyperfiltration,renal endothelial dysfunction,and microalbuminuria of incipient diabetic nephropathy in patients[J].Diabetes,2005,54(7):2206-2211.

同被引文献41

引证文献4

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部